Apexian Pharmaceuticals licenses IU discoveries

INDIANAPOLIS, IN—¬†Apexian Pharmaceuticals Inc., a biotechnology company focused on developing novel compounds to treat cancer, has licensed all technology discovered in Mark Kelley’s laboratory at the Indiana University School of Medicine. Read story on Indiana University website Indiana University Research and Technology Corp., which protects, markets and licenses intellectual property developed at IU so it can be commercialized by industry, issued the license. It allows … Read more…

Kelley, IU researchers awarded $2.9 million to study chemotherapy-induced peripheral neuropathy

Indiana University cancer researchers have been awarded $2.9 million to study the debilitating side effects caused by chemotherapy that affect a significant number of cancer patients. Mark R. Kelley, PhD, received the grant (1R01CA205166) from the National Cancer Institute to study chemotherapy-induced peripheral neuropathy (CIPN). Although cancer treatments are becoming more effective and people are consequently surviving cancer in increasing rates, many patients report neuropathy … Read more…